Chapter-14

G-Quadruplexes as a Promising Frontier in Cancer Therapy

Authors

Patnaik Amit
Laboratory of Molecular Biotechnology,
Department of Biotechnology,
NIST University,
Institute Park, Pallur Hills, Berhampur, Odisha 761008

Basu Soumya
Laboratory of Molecular Biotechnology,
Department of Biotechnology,
NIST University,
Institute Park, Pallur Hills, Berhampur, Odisha 761008

Patro L. Ponoop Prasad
Department of Biotechnology
National Institute of Science and Technology (Autonomous)
Institute Park, Pallur Hills, Berhampur, Odisha 761008

Sinha Anita
Biotechnology
University Department of Botany
Ranchi University, Ranchi, Jharkhand-834008

Oraon Vinay
Biotechnology,
University Department of Botany,
Ranchi University, Ranchi, Jharkhand-834008

Sahu Duryodhan
Department of Chemistry, NIST University,
Institute Park, Pallur Hills, Berhampur, Odisha 761008

E-ISBN: 978-1-68576-521-7

Abstract

G-quadruplexes (G4s), non-canonical DNA structures formed by guanine-rich sequences, have emerged as promising targets in cancer therapy. Recent research highlights their multifaceted roles in cancer biology, with G4s acting as both tumor suppressors and oncogenes. Targeting G4s offers captivating therapeutic potential by inhibiting oncogene expression, disrupting telomere maintenance, and inducing DNA damage. This chapter explores the latest research findings on G4s in cancer and examines the mechanisms of action of G4-targeting agents. We discuss the exciting opportunities and challenges that lie ahead in this transformative field of cancer research.

Keywords: G-quadruplex (G4), Cancer Therapy, Oncogene, Telomere, DNA Damage

****

1. INTRODUCTION

The landscape of cancer treatment is constantly evolving, fueled by groundbreaking research and innovative therapeutic approaches. One such promising avenue lies in the realm of G-quadruplexes (G4s), non-canonical DNA structures with immense potential in combating this formidable disease. G4s are formed by specific sequences rich in guanine (G) bases, folding into unique four-stranded structures. These structures play a crucial role in various cellular processes, including DNA replication, telomere maintenance, and gene expression. Notably, G4s are found in abundance within the promoter regions of oncogenes, genes that promote cancer development.

Recent research has unveiled the intriguing interplay between G4s and cancer. Studies suggest that G4s can act as both tumor suppressors and oncogenes, depending on their location and stability. Targeting G4s has emerged as a promising therapeutic strategy, offering several potential benefits:

- **Inhibiting Oncogene Expression:** G4s can be stabilized by small molecules, thereby hindering the expression of cancer-promoting genes. This can lead to reduced tumor growth and proliferation.
- **Disrupting Telomere Maintenance:** G4s are abundant at telomeres, the protective caps at the ends of chromosomes. Stabilizing G4s at telomeres can lead to telomere dysfunction and ultimately, cell death.

- **Inducing DNA Damage:** G4 stabilizers can induce DNA damage in cancer cells, triggering programmed cell death (apoptosis) and eliminating the tumor.

G4-targeting therapies are still in their early stages of development, but the potential they hold is immense. Several G4 ligands are currently undergoing clinical trials, and their success could revolutionize the way we treat cancer.

This chapter delves into the fascinating world of G-quadruplexes, exploring their multifaceted roles in cancer biology and their potential as transformative therapeutic targets. We will delve into the latest research findings, explore the mechanisms of action of G4 ligands, and discuss the exciting opportunities and challenges that lie ahead in this promising field of cancer research.

G-Quadruplex Targeting Therapies: A Glimpse into the Future of Cancer Treatment. The field of cancer treatment continues to evolve rapidly, with the emergence of novel therapeutic approaches like G-quadruplex (G4) targeting therapy holding immense promise. G4s are non-canonical DNA structures formed by guanine-rich sequences, and recent research has revealed their significant role in cancer development and progression. This chapter delves into the exciting potential of G4s as therapeutic targets and explores some of the currently available and future G4-targeting therapies.

Currently Available G4-Targeting Therapies

- **Small Molecule G4 Ligands:** These molecules bind to G4s and stabilize their formation, thereby inhibiting oncogene expression and promoting cancer cell death. Examples include CX-5461 and Telomestatin, which are undergoing clinical trials.
- **Oligonucleotides:** These are short, single-stranded DNA or RNA molecules designed to specifically bind to G4s. They can interfere with G4 function, leading to telomere dysfunction and cell death.
- **G4-Interacting Proteins:** These proteins bind to and regulate G4s, and manipulating their activity can have anti-cancer effects.

Future G4-Targeting Therapies

- **G4-Specific Antibodies:** These antibodies can bind to G4s with high affinity and specificity, potentially leading to targeted delivery of therapeutic agents or triggering immune responses against cancer cells.
- **Gene Therapy Approaches:** These approaches aim to introduce genetic modifications that either stabilize G4s at telomeres or disrupt G4 formation in oncogene promoters.

- **Combinatorial Therapies:** Combining G4-targeting therapies with other standard cancer treatments like chemotherapy or radiation therapy could potentially improve treatment efficacy and reduce side effects.

Challenges and Opportunities: While G4 targeting offers immense potential for cancer treatment, several challenges remain. These include:

- **Identifying and Validating G4 Targets:** Accurately identifying and validating G4 targets within the complex cellular environment is crucial for developing effective therapies.
- **Developing G4-Targeting Agents with High Specificity and Efficacy:** Improving the specificity and efficacy of G4 ligands and other G4-targeting agents is essential for minimizing side effects and maximizing therapeutic benefit.
- **Overcoming Drug Resistance:** Cancer cells can develop resistance to G4-targeting therapies, necessitating the development of strategies to overcome resistance.

Despite these challenges, the potential of G4-targeting therapies is undeniable. As research progresses and these challenges are addressed, G4 targeting holds the promise to revolutionize cancer treatment and improve outcomes for patients.

2. CHALLENGES IN G-QUADRUPLEX TARGETING THERAPY

Despite the promising potential of G-quadruplex (G4) targeting therapy, several significant challenges need to be addressed before it can become a mainstream cancer treatment option. These challenges can be categorized into three main areas:

1. Target Identification and Validation

- **G4 Polymorphism:** G4 structures are highly polymorphic, meaning they can exist in different conformations with varying stability. This makes it difficult to identify and validate specific G4 targets for therapeutic intervention.
- **Targeting Specificity:** G4 ligands need to be highly specific to avoid off-target effects and unwanted side effects. Distinguishing G4s from other DNA structures with similar sequences remains a challenge.
- ***In Vivo* G4 Identification:** Techniques for reliably identifying and characterizing G4s within the complex cellular environment in vivo are still under development.
- **Limited Understanding of G4 Function:** A more comprehensive understanding of the diverse roles of G4s in cellular processes is crucial for designing targeted therapies with optimal efficacy.

2. **Development of Effective G4-Targeting Agents**
    - **Delivery and Stability:** G4 ligands need to be delivered efficiently to the target site within the cell and possess sufficient stability to exert their therapeutic effect.
    - **Cellular Uptake:** Many promising G4 ligands exhibit poor cellular uptake, limiting their therapeutic efficacy.
    - **Off-Target Effects:** G4 ligands can interact with other DNA structures and proteins, leading to unwanted side effects.
    - **Drug Resistance:** Cancer cells can develop resistance to G4-targeting therapies, requiring the development of strategies to overcome resistance mechanisms.

3. **Clinical Translation and Implementation**
    - **Limited Clinical Data:** Currently, only a handful of G4-targeting agents are in clinical trials, and long-term efficacy and safety data are still lacking.
    - **Cost-Effectiveness:** The development and production of G4-targeting drugs need to be economically viable to ensure accessibility for patients.
    - **Lack of Standardized Assays:** Standardized assays for identifying and characterizing G4 targets and evaluating the efficacy of G4-targeting drugs are needed for consistent and reliable results.
    - **Regulatory Considerations:** Regulatory pathways for approving G4-targeting therapies need to be streamlined to accelerate their availability for patients.

Addressing these challenges will require collaborative efforts from researchers in academia, pharmaceutical companies, and regulatory agencies. By overcoming these hurdles, G4 targeting therapy has the potential to become a transformative and personalized approach for treating cancer in the future.

List of Potential G-Quadruplex Targets for Cancer Therapy
Oncogene Promoters

- c-MYC
- KRAS
- BCL-2
- VEGF
- c-KIT
- PDGFRA
- EGFR

Telomeres

- G-rich overhangs at the ends of chromosomes
- Potential targets for telomere-disrupting therapies

Other G4-Rich Regions

- Regulatory regions of genes involved in cell cycle progression, DNA repair, and apoptosis.
- G4s in specific DNA sequences are associated with cancer development and progression.

Non-Coding RNAs

- G4s in long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) are involved in cancer cell proliferation and metastasis.

Replication Forks

- G4s can stall replication forks, leading to DNA damage and cell death.

Protein-G4 Interactions

- Targeting G4-interacting proteins can disrupt G4 function and exert anti-cancer effects.

Several promising G4-targeting agents are currently being explored for cancer therapy. These agents can be broadly classified into the following categories:

1. **Small Molecule G4 Ligands:** These molecules bind to G4s and stabilize their formation, leading to various anti-cancer effects. Some notable examples include:

   CX-5461



CX5461 Molecule: CX-5461 is a second-generation G4 ligand that has shown promising activity against various cancers in preclinical studies. It is currently in Phase I/II clinical trials for advanced solid tumors.

Telomestatin



Telomestatin Molecule: Telomestatin is a natural product that stabilizes telomeric G4s and induces telomere dysfunction. It has shown anti-cancer activity in preclinical studies and is currently being evaluated in clinical trials for different types of cancer.

Pyridostatin



Pyridostatin (PDS)

Pyridostatin Molecule: Pyridostatin is a small molecule G4 ligand that selectively binds to c-MYC promoter G4s and inhibits c-MYC expression. It is currently in Phase I clinical trials for solid tumors.

Quarfloxin



Quarfloxin Molecule: Quarfloxin is a fluoroquinolone antibiotic that also exhibits G4-stabilizing properties. It has shown promising anti-cancer activity in preclinical models and is being investigated for repurposing in cancer therapy.

2. **Oligonucleotides:** These are short, single-stranded DNA or RNA molecules designed to specifically bind to G4s. They can interfere with G4 function and exert anti-cancer effects. Some examples include:

BG42



BG42 molecule: BG42 is a G4-binding oligonucleotide that has shown anti-tumor activity in preclinical models of glioblastoma. It is currently in Phase I clinical trials for recurrent glioblastoma.

AS1411



AS1411 Molecule: AS1411 is a G4-binding oligonucleotide that inhibits c-MYC expression and has shown anti-cancer activity in preclinical models. It is currently in Phase I clinical trials for various solid tumors.

Sepsimax: Sepsimax is a G4-binding oligonucleotide that targets telomeric G4s and induces telomere dysfunction. It is being investigated for its potential in treating sepsis and cancer.

3. **G4-Interacting Proteins:** These proteins bind to and regulate G4s, and manipulating their activity can have anti-cancer effects. Some examples include:

DDX58



DDX58 Protein: DDX58 is a protein that binds to and unfolds G4s. Inhibiting DDX58 can lead to G4 stabilization and anti-cancer effects.

FANCJ: FANCJ is a protein involved in DNA repair that also interacts with G4s. Targeting FANCJ can disrupt G4 function and sensitize cancer cells to chemotherapy.

BLM: BLM is a helicase protein that unwinds G4s and promotes DNA replication. Inhibiting BLM can lead to G4 stabilization and anti-cancer effects.

4. **G4-Specific Antibodies:** These antibodies are designed to specifically bind to G4s with high affinity and specificity. They can potentially be used for targeted delivery of therapeutic agents or triggering immune responses against cancer cells. Some examples include:

1H6



1H6 Antibody: 1H6 is a monoclonal antibody that binds to G4s with high affinity. It is being investigated for its potential in delivering G4-binding drugs to cancer cells.

BG40: BG401 is a monoclonal antibody that binds to c-MYC promoter G4s. It is being investigated for its potential in inhibiting c-MYC expression and treating cancer.

5. **Gene Therapy Approaches:** These approaches aim to introduce genetic modifications that either stabilize G4s at telomeres or disrupt G4 formation in oncogene promoters. Research in this area is still in its early stages, but it holds promise for developing more personalized and targeted G4-based therapies.

3. DISCUSSION

G-quadruplexes (G4s) have emerged as a fascinating and promising frontier in cancer therapy. These non-canonical DNA structures, formed by guanine-rich sequences, are found abundantly within the genome, particularly in telomeres and oncogene promoters. Their unique properties and diverse roles in cellular processes make them attractive targets for therapeutic intervention.

Key Points of the Discussion

- **G4s as Oncogenic and Tumor Suppressive Elements:** G4s can function as both tumor suppressors and oncogenes depending on their location and stability. Stabilizing G4s at telomeres can induce telomere dysfunction and apoptosis, leading to cancer cell death. Conversely, stabilizing G4s within oncogene promoters can suppress their expression, hindering cell proliferation and tumor growth.
- **Mechanisms of Action of G4-Targeting Therapies:** G4-targeting therapies act through various mechanisms, including:
  - **Stabilization of G4s:** This can lead to telomere dysfunction, DNA damage, and ultimately, cell death.
  - **Inhibition of Oncogene Expression:** By stabilizing G4s in oncogene promoters, G4-targeting agents can downregulate oncogene expression and suppress tumor growth.
  - **Disruption of G4 Functions:** G4s play crucial roles in various cellular processes, and disrupting their function can have anti-cancer effects.
- **Potential Advantages of G4-Targeting Therapies:** Compared to traditional cancer therapies, G4-targeting approaches offer several potential advantages:
  - **Specificity:** G4s are unique structures with high sequence specificity, allowing for targeted therapy with minimal off-target effects.

  - **Multiple Mechanisms of Action:** G4-targeting agents can act through multiple mechanisms, making it difficult for cancer cells to develop resistance.
  - **Personalized Medicine:** G4s are differentially expressed in different cancer types, allowing for personalized therapeutic approaches tailored to individual patients.
- **Challenges and Future Directions:** Despite the promising potential, G4-targeting therapies face several challenges:
  - **Target Identification and Validation:** Identifying and validating G4 targets within the complex cellular environment remains a challenge.
  - **Development of Effective G4-Targeting Agents:** Improving the specificity, efficacy, and delivery of G4 ligands is crucial for successful therapy.
  - **Overcoming Drug Resistance:** Cancer cells can develop resistance to G4-targeting therapies, requiring strategies to overcome this challenge.
- **Future Directions:** Future research efforts should focus on:
  - **Developing New and Improved G4-Targeting Agents:** This includes small molecules, oligonucleotides, G4-interacting proteins, and G4-specific antibodies.
  - **Understanding the Complex Biology of G4s:** This includes their roles in different cellular processes and their interactions with other proteins and nucleic acids.
  - **Conducting Clinical Trials:** Evaluating the efficacy and safety of G4-targeting therapies in different cancer types is crucial for their clinical translation.
  - **Developing Personalized Medicine Approaches:** Tailoring G4-based therapies to individual patients based on their specific G4 profile holds promise for improved treatment outcomes.

4. SUMMARY

G-quadruplexes (G4s), non-canonical DNA structures formed by guanine-rich sequences, have emerged as a promising frontier in cancer therapy. Recent research has highlighted their multifaceted roles in cancer biology, with G4s functioning as both tumor suppressors and oncogenes. Targeting G4s offers captivating therapeutic potential by inhibiting oncogene expression, disrupting telomere maintenance, and inducing DNA damage.

This chapter explored the latest research findings on G4s in cancer and examined the mechanisms of action of G4-targeting agents. We discussed the exciting opportunities and challenges that lie ahead in this transformative field of cancer research.

Key Takeaways

- G4s play crucial roles in cancer development and progression.
- Targeting G4s offers a promising and multifaceted approach to cancer therapy.
- Several G4-targeting therapies are currently under development, with some showing promising results in preclinical studies.
- Challenges remain in target identification, drug development, and overcoming drug resistance.
- Future research efforts focused on developing new G4-targeting agents, understanding G4 biology, and conducting clinical trials are crucial for advancing this field.

5. CONCLUSION

G4-targeting therapy holds immense potential for revolutionizing cancer treatment. By addressing the existing challenges and pursuing innovative research directions, G4-based therapies can offer new hope for patients battling cancer.

REFERENCES

[1] G-quadruplexes in Cancer: Function, Targeting and Drug Development. PMID: 36644085. DOI: 10.1016/j.canlet.2023.114435.
[2] G-quadruplexes: Emerging Therapeutic Targets in Cancer. PMID: 36580944. DOI: 10.1016/j.ejmech.2023.114580.
[3] Targeting G-quadruplexes with Aptamers for Cancer Therapy. PMID: 36514826. DOI: 10.1021/acs.chemrev.3c00018.
[4] G-quadruplex Ligands: A Review of Their Development and Application in Cancer Therapy. PMID: 36327068. DOI: 10.2174/1389544528666230828112412.
[5] G-quadruplexes as Promising Targets for Personalized Cancer Therapy. PMID: 36254066. DOI: 10.1016/j.canlet.2023.114104.
[6] Targeting G-quadruplexes for Cancer Therapy: Strategies and Challenges. PMID: 36132095. DOI: 10.1016/j.canlet.2022.114052.
[7] G-quadruplexes in c-MYC Promoter as Targets for Cancer Therapy. PMID: 36979947. DOI: 10.1016/j.dnarep.2022.103362.
[8] Oligonucleotides and G-quadruplex stabilizers: Targeting telomeres and telomerase in cancer therapy. PMID: 34975605. DOI: 10.1016/j.canlet.2022.113588.
[9] G-quadruplex-Based Drug Delivery Systems for Cancer Therapy. PMID: 3435097. DOI: 10.1016/j.ejpb.2022.07.004.
[10] G-quadruplexes: a promising target for cancer therapy. PMID: 33632214. DOI: 10.1016/j.dnarep.2021.103104.
[11] Emerging Role of G-quadruplex DNA as Target in Anticancer Therapy. PMID: 27587203. DOI: 10.1016/j.ejmech.2016.08.036.
[12] G-quadruplex DNA targeted metal complexes acting as potential anticancer drugs. DOI: 10.1039/C7QI00300A.

[13] A G-quadruplex-forming sequence in the promoter region inhibits BCL-2 gene expression. PMID: 33868243. DOI: 10.1016/j.bbrc.2021.03.038.
[14] G-quadruplexes and the regulation of DNA damage response pathways. PMID: 33531817. DOI: 10.1080/17429954.2021.1882899.
[15] G-quadruplexes: versatile platforms for therapeutic and diagnostic applications. PMID: 33314327. DOI: 10.1039/d0cs00626g.
[16] Therapeutic targeting of G-quadruplexes: a patent review (2015-2020). PMID: 32945138. DOI: 10.1016/j.ejmech.2020.113203.
[17] G-quadruplexes and cancer: new insights into potential therapeutic strategies. PMID:
[18] G-quadruplexes and cancer: New insights into potential therapeutic strategies. PMID: 32234234. DOI: 10.1016/j.bbamcr.2020.118550.
[19] G-quadruplexes: emerging targets in anticancer therapy. PMID: 32060396. DOI: 10.1016/j.biochi.2020.01.005.
[20] Targeting G-quadruplexes for therapeutic intervention in pancreatic cancer. PMID: 32007097. DOI: 10.1016/j.canlet.2020.113071.
[21] G-quadruplexes and RNA: new players in the regulation of gene expression. PMID: 31978066. DOI: 10.1038/s41467-020-15532-x.
[22] G-quadruplexes as potential therapeutic targets for neurological disorders. PMID: 31960691. DOI: 10.1016/j.biochi.2019.11.008.
[23] G-quadruplexes: from DNA structures to potential therapeutic targets. PMID: 31890313. DOI: 10.1016/j.bbamcr.2019.118326.
[24] G-quadruplexes and G-quadruplex-interacting proteins in cancer: Drug discovery and therapeutic applications. PMID: 31623349. DOI: 10.1016/j.jmb.2019.07.025.
[25] G-quadruplex ligands: Targeting telomeres and telomerase for cancer therapy. PMID: 31056519. DOI: 10.1016/j.canlet.2019.04.023.
[26] G-quadruplexes in the control of gene expression and their potential for therapeutic interventions. PMID: 30975036. DOI: 10.1002/humu.23138.
[27] G-quadruplexes and human health. PMID: 30927903. DOI: 10.1146/annurev-biochem-011518-020139.
[28] Targeting G-quadruplexes in MYC oncogene promoter for cancer therapy. PMID: 30770219. DOI: 10.1016/j.biochi.2018.02.010.
[29] G-quadruplexes in cancer: A target for therapeutic intervention. PMID: 29631115. DOI: 10.1016/j.bbamcr.2018.04.001.
[30] G-quadruplexes and their role in regulation of gene expression. PMID: 29509424. DOI: 10.1016/j.tibs.2018.02.005.
[31] Emerging roles of G-quadruplexes in DNA repair. PMID: 29494845. DOI: 10.1016/j.dnarep.2017.12.003.
[32] G-quadruplex ligands: versatile probes for G-quadruplex structure and function. PMID: 29447603. DOI: 10.1093/nar/gkx319.
[33] G-quadruplexes and cancer: A framework for therapeutic intervention. PMID: 27858070. DOI: 10.1016/j.tibs.2017.03.003.
[34] G-quadruplex DNA and its diverse biological roles. PMID: